2017
Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis
Search citation statements
Paper Sections
Select...
36
3
2
1
Citation Types
1
23
1
1
Year Published
2017
2026
Publication Types
Select...
37
3
1
Relationship
2
39
Authors
Journals
Cited by 41 publications
(26 citation statements)
References 32 publications
1
23
1
1
“…Importantly, the 20% increase in NE exposure is also not considered clinically relevant in terms of safety, as NE doses higher than the one used in the present study (eg, up to 5 mg daily) are approved for the treatment of menstrual irregularities and endometriosis and have been shown to be well tolerated in long-term studies for up to 5 years. 22 The observed effect of repeat-dose trametinib on the PK of COCs in this study in female individuals is in line with the expected in vivo effect of trametinib on COCs, which was based on preclinical in vitro data. Although trametinib has been shown to be a weak inducer of CYP3A4 with an EC 50 of 1.7 μM in vitro (Novartis, unpublished data) the clinically relevant systemic concentration of trametinib is lower (≈0.04 μM 15 ) than the observed in vitro induction value of CYP3A4, suggesting that an in vivo effect of trametinib on COC exposure is unlikely.…”
Section: Discussionsupporting
confidence: 87%
“…Importantly, the 20% increase in NE exposure is also not considered clinically relevant in terms of safety, as NE doses higher than the one used in the present study (eg, up to 5 mg daily) are approved for the treatment of menstrual irregularities and endometriosis and have been shown to be well tolerated in long-term studies for up to 5 years. 22 The observed effect of repeat-dose trametinib on the PK of COCs in this study in female individuals is in line with the expected in vivo effect of trametinib on COCs, which was based on preclinical in vitro data. Although trametinib has been shown to be a weak inducer of CYP3A4 with an EC 50 of 1.7 μM in vitro (Novartis, unpublished data) the clinically relevant systemic concentration of trametinib is lower (≈0.04 μM 15 ) than the observed in vitro induction value of CYP3A4, suggesting that an in vivo effect of trametinib on COC exposure is unlikely.…”
Section: Discussionsupporting
confidence: 87%
“…It has been previously reported that hormonal therapies can decrease the size of deep endometriotic nodules [18,30]; however, it seems that there is no direct correlation between improvement of symptoms and decrease in nodule volume [30]. In our study, at the end of follow-up visits under DNG therapy, a mean nodule volume reduction of at least 10% was reported by around 30% of women.…”
Section: Discussioncontrasting
confidence: 68%
“…Given the study design adopted, a placebo effect cannot be excluded, because the rationale for such diverse effects of same-class compounds is unclear. In addition, the long-term effectiveness of NETA has been confirmed in a retrospective cohort study conducted by this research group on 103 patients with symptomatic rectovaginal endometriosis and followed for 5 years (64). A total of 16 women discontinued the progestin because of adverse effects.…”
Section: Estrogen-progestins and Progestinsmentioning
confidence: 81%
